Baird analyst Brian Skorney raised the firm’s price target on Soleno Therapeutics (SLNO) to $105 from $102 and keeps an Outperform rating on the shares. The firm said 268 start forms in one month is a very good beginning to its launch.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue